Vertex Pharma upgraded at Canaccord Genuity after Q4 results
Vertex Pharmaceuticals (NASDAQ:VRTX) received an upgrade from Canaccord Genuity after the cystic fibrosis drugmaker exceeded consensus revenue estimates but missed on earnings with its Q4 2024 ...
Healthcare Dive20h
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Hosted on MSN22h
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...
studyfinds23h
How the brain can miraculously switch off pain
Unlock the mysteries of pain management by harnessing the power of fear, stress, and emotion. Discover how the brain's response to pain can be altered for more effective pain relief.